Drugs / GPC2 CAR T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07087002 | Aug 2025 → Aug 2027 expected | atypical teratoid rhabdoid tumor, cns neuroblastoma with FOXR2 activation, embryonal tumor with multilayered rosettes, medulloblastoma +1 | Stanford University | Recruiting | No outcome recorded |
| Phase 1 | NCT05650749 | May 2023 → Jan 2028 expected | neuroblastoma, retinoblastoma | Stephan Grupp MD PhD | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GPC2-CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07087002 ↗ |
| Action | Deplete | “Second-generation D3-GPC2 CAR T cells with either a 4-1BB or CD28 co-stimulatory domain were selectively activated and induced potent neuroblastoma cell cytotoxicity in several...” PMID 41026583 ↗ Dec 2025 |
| Modality | Cell therapy | “The GPC2 CAR T investigational product is comprised of autologous human T cells that have been genetically modified to express a GPC2-targeting chimeric antigen receptor (CAR)...” NCT05650749 ↗ |
| Route | Other | “administered intracerebroventricularly” NCT07087002 ↗ |
| Target | GPC2 | “The GPC2 CAR T investigational product is comprised of autologous human T cells that have been genetically modified to express a GPC2-targeting chimeric antigen receptor (CAR)...” NCT05650749 ↗ |